IP Library Granted Patent US 9,949,959
Granted Patent B2
US 9,949,959 · App. 15/098,970 · Granted Apr 24, 2018

Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne

Inventors: Juan Socorro Armendáriz Borunda (Mexico City, MX); José Agustín Rogelio Magaña Castro (Mexico City, MX); Pedro Peña Santoyo (Mexico City, MX); Laura Vázquez Cervantes (Mexico City, MX)
Assignee: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.
A61K31/4412A61K9/0014A61K9/06A61K31/351A61K31/4418
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,959
App. No.
15/098,970
Granted
Apr 24, 2018
Kind
B2
Abstract

The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. Said compositions is also useful for reducing skin redness, detaining the formation of new acne outbreaks, reversing already existing outbreaks and regenerating skin damage caused by acne.

Claims (9)

1. A semi-solid topical composition for eliminating or reducing skin acne occurrence, comprising 2%, 4%, 6%, 8% or 10% in weight of pirfenidone, 0.016% in weight of {[1,2-diallyl-1-(5-methyl-tetrahydro-2H-pyran-2-yloxy)disulfonium]+6-[(benzyl, methyl, octylammonium)(hydroxymethylamin)(methylamin)]-tetrahydro-2H-pyran-3-oxy]}chloride (M-DDO), and 91.984% in weight of a gelling agent and other excipients or additives.

2. The semi-solid topical composition according to claim 1 , comprising 8% in weight of the pirfenidone, 0.016% in weight of the M-DDO and 91.984% in weight of the gelling agent and other excipients or additives.

3. The semi-solid topical composition according to claim 1 , wherein the gelling agent is selected from the group consisting of methylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpirrolidone, carboxyvinyl polymers, carbomer and acrylic polymers.

4. The semi-solid topical composition according to claim 3 , wherein the gelling agent is carbomer.

5. The semi-solid topical composition according to claim 1 , wherein the excipients or additives are selected from the group consisting of propylene glycol as a solubilizer, macrogol-glycerol hydroxystearate as a non-ionic solubilizer and triethanolamine as a neutralizing agent.

6. The semi-solid topical composition according to claim 1 , wherein said composition is in gel, cream or ointment form.

7. The semi-solid topical composition according to claim 1 , having a pH of 5 to 6.4.

8. A method of eliminating or reducing acne, comprising administering a semi-solid topical composition according to claim 1 to the skin of a person in need thereof.

9. A method for eliminating or reducing chronic inflammation caused by acne, reducing skin redness, reversing existing outbreaks, regenerating skin damage caused by acne and/or removing post-acne scars, the method comprising administering a semi-solid topical composition according to claim 1 to the skin of a person in need thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: CELL THERAPY TECHNOLOGY S.A. DE C.V.
To: EXCALIBUR PHARMACEUTICALS, INC.
Reel/Frame 053418/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2016
From: ARMENDÁRIZ BORUNDA, JUAN SOCORRO; MAGAÑA CASTRO, JOSÉ AGUSTÍN ROGELIO; PEÑA SANTOYO, PEDRO; VÁZQUEZ CERVANTES, LAURA
To: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.
Reel/Frame 038417/0980 →
Priority Claims (1)
MX MX/a/2012/003694 · Mar 28, 2012 · national
Continuity (2)
Continuation 14388447
Related Publication 20160228424A1 · Aug 11, 2016